ArticleCancer discovery2023

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.

Vivek Subbiah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.